rs727503926
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The ENST00000366560.4(FH):c.1154C>A(p.Ala385Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000137 in 1,461,816 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. A385A) has been classified as Likely benign.
Frequency
Consequence
ENST00000366560.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FH | NM_000143.4 | c.1154C>A | p.Ala385Asp | missense_variant | 8/10 | ENST00000366560.4 | NP_000134.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FH | ENST00000366560.4 | c.1154C>A | p.Ala385Asp | missense_variant | 8/10 | 1 | NM_000143.4 | ENSP00000355518 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461816Hom.: 0 Cov.: 31 AF XY: 0.00000275 AC XY: 2AN XY: 727208
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:3Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jun 25, 2022 | This variant has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). In the published literature, the variant has been reported in individuals with HLRCC and to segregate with disease in one affected family (PMIDs: 23211287 (2013), 15937070 (2006)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, this variant is classified as likely pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 07, 2024 | This sequence change replaces alanine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 385 of the FH protein (p.Ala385Asp). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with hereditary leiomyomatosis and renal cell cancer (PMID: 15937070; Invitae). It has also been observed to segregate with disease in related individuals. This variant is also known as c.1025C>A, p.Ala342Asp. ClinVar contains an entry for this variant (Variation ID: 167065). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FH protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 18, 2023 | Segregates with disease in multiple individuals with features of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) from several families referred for genetic testing at GeneDx and in published literature (Wei 2006, Sanz-Ortega 2013); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as c.1025C>A, p.Ala342Asp; This variant is associated with the following publications: (PMID: 21398687, 21445611, 21340633, 15937070, 23211287) - |
Uncertain significance, flagged submission | clinical testing | Eurofins Ntd Llc (ga) | Jan 06, 2014 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 02, 2024 | The p.A385D pathogenic mutation (also known as c.1154C>A), located in coding exon 8 of the FH gene, results from a C to A substitution at nucleotide position 1154. The alanine at codon 385 is replaced by aspartic acid, an amino acid with dissimilar properties. This alteration has been identified in at least two families with multiple cutaneous and uterine leiomyomas and diagnosis of hereditary leiomyomatosis and renal cell carcinoma (HLRCC) (Wei MH et al. J. Med. Genet. 2006 Jan; 43(1):18-27; Ambry internal data). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Hereditary leiomyomatosis and renal cell cancer Uncertain:1
Uncertain significance, flagged submission | clinical testing | Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia | Jan 17, 2017 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at